Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The company also has relacorilant in studies ...

Peter Marks’ March 28 letter giving one week’s notice of his resignation as director of the U.S. FDA’s Center for Biologics Evaluation and Research (CBER) is sending more ripples of uncertainty ...

In the brain, molecular information is transmitted between cells through neural circuits. Synapses establish connections between the pathways that run from one area to another, allowing the most ...

Medtronic plc’s Evolut Low-Risk trial continued to show non-inferiority of transcatheter aortic valve replacement to surgical ...

Sanofi SA gained U.S. FDA approval for fitusiran as a first-in-class siRNA therapy for hemophilia. Branded Qfitlia, the ...

Digital therapeutics coupled with drugs has the potential to transform health care and change the way patients are treated, ...

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies activating the immune system to kill tumor cells, representing a major advancement in cancer treatment. However, by activating T-cell ...

Research published online in Nature on March 19, 2025, closely examines the changes occurring in the gastric epithelium during the progression toward cancer development. Certain mutations that occur ...

It was a mixed day for Daewoong Pharmaceutical Co. Ltd., which disclosed separately on March 28 both the termination of a ...

Researchers from the University of Queensland recently provided details on the discovery and preclinical characterization of ...

Australia’s top universities are looking more to Asia for research collaborations following threats from the Trump ...

In February 2025, BioWorld recorded 148 updates from phase I to phase III trials, marking a decline from the 171 updates tracked in January.